The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic ...

Cipla's Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic ...

The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.

Although the medical condition acromegaly may be fairly rare, for those who do live with the hormone disorder, it can cause a ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used ...

The wholly-owned subsidiary Cipla USA Inc has received the final approval for the Abbreviated New Drug Application (ANDA) of ...

Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal ...

Crinetics just released initial data from its phase 2 open-label study using its drug Atumelnant. Read why I'm bullish on ...

This came after the company's announced on Friday, May 17 that it has bagged an order worth Rs 250 crore from Northern Coal ...

Mumbai-headquartered pharma major Cipla US arm has secured final approval from the United States Food and Drug Administration USFDA for its Lanreotide Inje ...

The abstract for the Phase 2, open-label study of atumelnant* (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. We plan to present ...